Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near-term milestone payments and is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE WOODLANDS, Texas, March 23, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and Novo Nordisk A/S today announc ...